Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

By Raz Itamar   Chen Yu   Wu Mei   Hussain Shehla   Kaufman Keith D.   Amatruda John M.   Langdon Ronald B.   Stein Peter P.   Alba Maria  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 537-550

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug‐naïve patients with type 2 diabetes: a randomized, double‐blind, 6‐month study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 613-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 530-540

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 849-858

John Wiley & Sons Inc

Access to resources Recommend Favorite